ATE516366T1 - Regulierte aptamer-therapeutika - Google Patents

Regulierte aptamer-therapeutika

Info

Publication number
ATE516366T1
ATE516366T1 AT03771887T AT03771887T ATE516366T1 AT E516366 T1 ATE516366 T1 AT E516366T1 AT 03771887 T AT03771887 T AT 03771887T AT 03771887 T AT03771887 T AT 03771887T AT E516366 T1 ATE516366 T1 AT E516366T1
Authority
AT
Austria
Prior art keywords
aptamer therapeutics
regulated aptamer
therapeutic compositions
presented
methods
Prior art date
Application number
AT03771887T
Other languages
English (en)
Inventor
David Epstein
Charles Wilson
John Diener
Original Assignee
Archemix Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Archemix Corp filed Critical Archemix Corp
Application granted granted Critical
Publication of ATE516366T1 publication Critical patent/ATE516366T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1048—SELEX
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Emergency Medicine (AREA)
AT03771887T 2002-07-25 2003-07-25 Regulierte aptamer-therapeutika ATE516366T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39848602P 2002-07-25 2002-07-25
US39886302P 2002-07-25 2002-07-25
PCT/US2003/023402 WO2004011680A1 (en) 2002-07-25 2003-07-25 Regulated aptamer therapeutics

Publications (1)

Publication Number Publication Date
ATE516366T1 true ATE516366T1 (de) 2011-07-15

Family

ID=32475361

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03771887T ATE516366T1 (de) 2002-07-25 2003-07-25 Regulierte aptamer-therapeutika

Country Status (7)

Country Link
US (2) US20040110235A1 (de)
EP (1) EP1543158B1 (de)
JP (1) JP2005533862A (de)
AT (1) ATE516366T1 (de)
AU (1) AU2003261264B2 (de)
CA (1) CA2492463A1 (de)
WO (1) WO2004011680A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2070939B1 (de) 2001-05-25 2014-04-02 Duke University Modulatoren von pharmakologischen Wirkstoffen
FR2867784B1 (fr) * 2004-03-17 2006-06-09 Commissariat Energie Atomique Aptameres selectionnes a partir de cellules vivantes tumorales et leurs applications
CN103045601B (zh) 2004-04-22 2015-04-01 雷加多生物科学公司 改良的凝血因子调节物
EP1742959A2 (de) * 2004-04-26 2007-01-17 Archemix Corporation Immunoglobulin e-nukleinsäureliganden und deren verwendung als therapeutika für atopische erkrankungen
US20090130650A1 (en) * 2006-02-17 2009-05-21 Weihong Tan Methods for the production of highly sensitive and specific cell surface probes
US20090117549A1 (en) * 2006-07-18 2009-05-07 Weihong Tan Aptamer-based methods for identifying cellular biomarkers
GB0719367D0 (en) 2007-10-03 2007-11-14 Procarta Biosystems Ltd Transcription factor decoys, compositions and methods
GB0906130D0 (en) * 2008-10-03 2009-05-20 Procrata Biosystems Ltd Transcription factor decoys
WO2010088286A1 (en) * 2009-01-28 2010-08-05 Smartcells, Inc. Synthetic conjugates and uses thereof
AU2010208295A1 (en) * 2009-01-28 2011-08-04 Smartcells, Inc. Polynucleotide aptamer-based cross -linked materials and uses thereof
JP2012526130A (ja) * 2009-05-05 2012-10-25 アルテルムネ テクフノロジエス，エルエルシー 化学的にプログラム可能な免疫
GB201002413D0 (en) 2010-02-12 2010-03-31 Procarta Biosystems Ltd Nucleic acid complexes
US10316320B2 (en) 2013-04-18 2019-06-11 Bar Ilan University Systems comprising non-immunogenic and nuclease resistant nucleic acid origami devices for molecular computation
WO2014170898A1 (en) * 2013-04-18 2014-10-23 Bar-Ilan University Non-immunogenic and nuclease resistant nucleic acid origami devices and compositions thereof
WO2016025750A2 (en) * 2014-08-13 2016-02-18 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for regulation of gene expression with, and detection of, folinic acid and folates
EP3330379B1 (de) * 2015-07-27 2021-10-27 Posco Aptamer gegen insulinrezeptor und pharmazeutische zusammensetzung damit
CN107083387A (zh) * 2016-10-17 2017-08-22 柳州立洁科技有限公司 一种高亲和力胰岛素核酸适体ins4及其制备方法
CN108613862B (zh) * 2018-05-10 2020-10-27 北京理工大学 一种基于毛细管电泳的双靶同步核酸适配体筛选方法
KR20230131326A (ko) * 2022-03-03 2023-09-13 주식회사 압타머사이언스 인슐린 수용체 특이적 압타머 및 이의 이용

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755295A (en) * 1969-10-24 1973-08-28 Syntex Corp 1-(2-amino-2-deoxy-{62 -d-ribofuranosyl) pyrimidines and derivatives thereof
US3710795A (en) * 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4959309A (en) * 1983-07-14 1990-09-25 Molecular Diagnostics, Inc. Fast photochemical method of labelling nucleic acids for detection purposes in hybridization assays
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE229046T1 (de) 1985-03-30 1987-12-17 Marc Genf/Geneve Ballivet Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
US4935363A (en) * 1987-03-30 1990-06-19 Board Of Regents, The University Of Texas System Sterol regulatory elements
WO1989006694A1 (en) 1988-01-15 1989-07-27 Trustees Of The University Of Pennsylvania Process for selection of proteinaceous substances which mimic growth-inducing molecules
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5118672A (en) * 1989-07-10 1992-06-02 University Of Georgia Research Foundation 5'-diphosphohexose nucleoside pharmaceutical compositions
US5070010A (en) * 1989-10-30 1991-12-03 Hoffman-La Roche Inc. Method for determining anti-viral transactivating activity
CA2069948A1 (en) * 1989-12-01 1991-06-02 Brian Wylie Pontius Promotion of high specificity molecular assembly
JPH05501060A (ja) 1990-03-21 1993-03-04 アイシス・ファーマシューティカルス・インコーポレーテッド Ｒｎａ模倣による遺伝子発現活性変調のための試薬および方法
ATE154981T1 (de) * 1990-04-06 1997-07-15 Perkin Elmer Corp Automatisiertes labor für molekularbiologie
US5567588A (en) * 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5763177A (en) * 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5503978A (en) * 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
US5763173A (en) * 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand inhibitors to DNA polymerases
US5476766A (en) * 1990-06-11 1995-12-19 Nexstar Pharmaceuticals, Inc. Ligands of thrombin
US5637459A (en) * 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US5789157A (en) * 1990-06-11 1998-08-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US5580737A (en) * 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5459015A (en) * 1990-06-11 1995-10-17 Nexstar Pharmaceuticals, Inc. High-affinity RNA ligands of basic fibroblast growth factor
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5683867A (en) * 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US6011020A (en) * 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5707796A (en) 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US5648214A (en) * 1990-06-11 1997-07-15 University Research Corporation High-affinity oligonucleotide ligands to the tachykinin substance P
US5861254A (en) 1997-01-31 1999-01-19 Nexstar Pharmaceuticals, Inc. Flow cell SELEX
US6465189B1 (en) * 1990-06-11 2002-10-15 Gilead Sciences, Inc. Systematic evolution of ligands by exponential enrichment: blended selex
US5475096A (en) 1990-06-11 1995-12-12 University Research Corporation Nucleic acid ligands
US5660985A (en) * 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5635615A (en) * 1990-06-11 1997-06-03 Nexstar Pharmaceuticals, Inc. High affinity HIV nucleocapsid nucleic acid ligands
US5705337A (en) * 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US6083696A (en) * 1990-06-11 2000-07-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands exponential enrichment: blended selex
US5654151A (en) * 1990-06-11 1997-08-05 Nexstar Pharmaceuticals, Inc. High affinity HIV Nucleocapsid nucleic acid ligands
EP0549692A4 (en) 1990-09-21 1993-08-25 Fred Hutchinson Cancer Research Center Protein sequence-specific oligonucleotide sequences
JP3257675B2 (ja) * 1990-10-12 2002-02-18 マックス−プランク−ゲゼルシャフト ツール フェルデルング デル ビッセンシャフテン エー．ファウ． 修飾リボザイム
JPH06508022A (ja) 1991-02-21 1994-09-14 ギリアド　サイエンシズ，インコーポレイテッド 生体分子に特異的なアプタマーおよび生産方法
WO1992014842A1 (en) 1991-02-21 1992-09-03 Gilead Sciences, Inc. Aptamers specific for thrombin and methods of use
US5605662A (en) * 1993-11-01 1997-02-25 Nanogen, Inc. Active programmable electronic devices for molecular biological analysis and diagnostics
US5720163A (en) * 1992-02-14 1998-02-24 Precision Combustion, Inc. Torch assembly
US5338671A (en) 1992-10-07 1994-08-16 Eastman Kodak Company DNA amplification with thermostable DNA polymerase and polymerase inhibiting antibody
US5262564A (en) * 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
JPH08507203A (ja) * 1992-12-04 1996-08-06 イノーバー ラボラトリーズ，インコーポレイテッド 調節可能な核酸治療およびそれらの使用方法
EP1195442A3 (de) * 1992-12-04 2002-07-31 Innovir Laboratories, Inc. Signalverstärkung mittels Ribozyme im Diagnoseverfahren
US5817635A (en) * 1993-08-09 1998-10-06 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Modified ribozymes
US5998142A (en) 1993-09-08 1999-12-07 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US5807718A (en) 1994-12-02 1998-09-15 The Scripps Research Institute Enzymatic DNA molecules
US5663064A (en) 1995-01-13 1997-09-02 University Of Vermont Ribozymes with RNA protein binding site
US6013443A (en) * 1995-05-03 2000-01-11 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
US5859228A (en) * 1995-05-04 1999-01-12 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
DE69638318D1 (de) * 1995-06-07 2011-02-17 Gilead Sciences Inc Nukleinsäureliganden, die an DNA-Polymerasen binden und diese inhibieren
US6229002B1 (en) * 1995-06-07 2001-05-08 Nexstar Pharmaceuticlas, Inc. Platelet derived growth factor (PDGF) nucleic acid ligand complexes
EP0922114B1 (de) 1996-08-26 2003-10-29 Genetico Ltd. Katalytische nukleinsäuren und deren medizinische verwendung
US6051698A (en) * 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
ATE318143T1 (de) 1996-10-25 2006-03-15 Gilead Sciences Inc Gefaesszellen wachstumsfaktor (vegf) nukleinsaureligand-komplexe
JP2002514913A (ja) * 1996-12-19 2002-05-21 エール ユニバーシティ 生反応性アロステリックポリヌクレオチド
US6001067A (en) * 1997-03-04 1999-12-14 Shults; Mark C. Device and method for determining analyte levels
DE19743518A1 (de) 1997-10-01 1999-04-15 Roche Diagnostics Gmbh Automatisierbare universell anwendbare Probenvorbereitungsmethode
EP1049803A4 (de) 1997-12-15 2002-08-21 Nexstar Pharmaceuticals Inc Gleichmässige erkennung von zielmolekül durch nukleinsäure ligand - beacon ligand interaktion
US5988142A (en) * 1997-12-22 1999-11-23 Stanadyne Automotive Corp. Duration control of common rail fuel injector
US6087102A (en) * 1998-01-07 2000-07-11 Clontech Laboratories, Inc. Polymeric arrays and methods for their use in binding assays
US6287765B1 (en) * 1998-05-20 2001-09-11 Molecular Machines, Inc. Methods for detecting and identifying single molecules
WO2000011446A2 (en) * 1998-08-21 2000-03-02 University Of Virginia Patent Foundation Signal generating oligonucleotide-based biosensor
IL126732A0 (en) 1998-10-23 1999-08-17 Intelligene Ltd Pro drug
IL126731A0 (en) 1998-10-23 1999-08-17 Intelligene Ltd A method of detection
EP1133513A4 (de) 1998-11-03 2002-07-03 Univ Yale Aus mehreren domänen von polynukleotiden bestehende molekulare sensoren
WO2000043534A1 (en) 1999-01-19 2000-07-27 Somalogic, Inc. Method and apparatus for the automated generation of nucleic acid ligands
US6329145B1 (en) * 1999-02-09 2001-12-11 Gilead Science, Inc. Determining non-nucleic acid molecule binding to target by competition with nucleic acid ligand
CA2373314C (en) 1999-05-14 2010-09-14 Brandeis University Nucleic acid-based detection
US6506887B1 (en) * 1999-07-29 2003-01-14 Somalogic, Incorporated Conditional-selex
EP1263947A2 (de) 2000-03-06 2002-12-11 Ribozyme Pharmaceuticals, Inc. Nukleinsäure sensormoleküle
JP2004515219A (ja) * 2000-06-15 2004-05-27 ボード・オブ・リージェンツ，ザ・ユニヴァーシティ・オヴ・テキサス・システム 調節可能な触媒活性な核酸
AU2001266917A1 (en) 2000-06-15 2001-12-24 Board Of Regents Allosterically regulated ribozymes
WO2002022882A2 (en) 2000-09-13 2002-03-21 Archemix Corporation Target activated nucleic acid biosensor and methods of using same
WO2003014375A2 (en) 2001-08-09 2003-02-20 Archemix Corporation Nucleic acid sensor molecules and methods of using same
US20030219422A1 (en) * 2001-11-15 2003-11-27 Noxxon Pharma Ag Allosteric ribozymes and uses thereof

Also Published As

Publication number Publication date
US7960102B2 (en) 2011-06-14
US20040110235A1 (en) 2004-06-10
EP1543158A1 (de) 2005-06-22
AU2003261264A1 (en) 2004-02-16
JP2005533862A (ja) 2005-11-10
EP1543158A4 (de) 2007-06-06
US20060084109A1 (en) 2006-04-20
EP1543158B1 (de) 2011-07-13
CA2492463A1 (en) 2004-02-05
AU2003261264B2 (en) 2008-12-11
WO2004011680A1 (en) 2004-02-05

Similar Documents

Publication Publication Date Title
ATE516366T1 (de) Regulierte aptamer-therapeutika
LTPA2017009I1 (lt) Brutono tirozinkinazės inhibitoriai
EA200700118A1 (ru) Амидосоединения и их применение в качестве лекарственных средств
MX2007004882A (es) Derivados de xantina con actividad de receptor de hm74a.
EA201791669A3 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
ATE497770T1 (de) Pharmazeutische formulierungen von decitabin
BRPI0418939A (pt) derivados de nicotinamida e sua utilização como agentes terapêuticos
ATE530544T1 (de) Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren
EA200870019A1 (ru) Лактамовые соединения и способы их применения
IL169896A0 (en) Methods and compositions for administering therapeutic and diagnostic agents
MEP35308A (en) COMPOUNDS SPECIFIC TO ADENOSINE A1, A2a, AND A3 RECEPTOR AND USES THEREOF
UY28945A1 (es) Derivados de pirrolopiridina
TW200630105A (en) Herbal composition PHY906 and its use in chemotherapy
EA200500986A1 (ru) Применение капсаициноидов
GEP20125565B (en) Lactam compounds and their pharmaceutical use
TW200637614A (en) Bendamustine pharmaceutical compositions
EA200602062A1 (ru) Амидосоединения и их применение в качестве фармацевтических средств
EA200971053A1 (ru) Способы лечения кожных язв
ATE543491T1 (de) Kombinationspräparat enthaltend ibuprofen und paracetamol
EA200700214A1 (ru) Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией
DE60320095D1 (de) Zusammensetzungen zur behandlung von hauterkrankungen
EA200600921A1 (ru) Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
WO2004026260A3 (en) Prophylactic and therapeutic hiv aptamers
NO20076405L (no) Anvendelse av 24-nor-UDCA

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties